690270-29-2

690270-29-2结构式

中文名	4'-C-迭氮基胞嘧啶核苷 2',3',5'-三异丁酸酯
英文名	isobutyric acid (2R,3S,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-2-azido-4-isobutyryloxy-2-isobutyryloxymethyltetrahydrofuran-3-yl ester
英文别名	Balapiravir (Ro Balapiravir (R1626) R-1626; R 1626; RO 4588161; R1626; RO4588161; RO-4588161 4'-C-Azidocytidine 2',3',5'-tris(2-methylpropanoate) R-1626 (2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-azido-2-((isobutyryloxy)methyl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate)

描述	Balapiravir (R1626, Ro 4588161)是R1479(RG1479)的原药,是HCV的RNA聚合酶核苷类似物抑制剂。
相关类别	信号通路 >> 抗感染 >> HCV 研究领域 >> 感染
参考文献	[1]. Nguyen NM, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):1442-1450. [2]. Nelson DR, et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.Ann Hepatol. 2012 Jan-Feb;11(1):15-31. [3]. Li F, et al. Chemical stability of 4'-azidocytidine and its prodrug balapiravir.Drug Dev Ind Pharm. 2010 Apr;36(4):413-20. [4]. kros PJ, et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.Hepatology. 2008 Aug;48(2):385-97. [5]. Roberts SK, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.Hepatology. 2008 Aug;48(2):398-406. [6]. Chen YL, et al. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. J Virol. 2014 Feb;88(3):1740-1747.